Monogram Orthopaedics (MGRM) Competitors

Tandem Diabetes Care (NASDAQ:TNDM) and Monogram Orthopaedics (NASDAQ:MGRM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Is TNDM or MGRM more profitable?

Monogram Orthopaedics has a net margin of 0.00% compared to Tandem Diabetes Care's net margin of -20.51%. Tandem Diabetes Care's return on equity of -65.40% beat Monogram Orthopaedics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-20.51%	-65.40%	-13.87%
Monogram Orthopaedics	N/A	-113.91%	-93.08%

Do institutionals and insiders have more ownership in TNDM or MGRM?

0.4% of Monogram Orthopaedics shares are owned by institutional investors. 1.9% of Tandem Diabetes Care shares are owned by insiders. Comparatively, 28.1% of Monogram Orthopaedics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the media refer more to TNDM or MGRM?

In the previous week, Tandem Diabetes Care had 29 more articles in the media than Monogram Orthopaedics. MarketBeat recorded 33 mentions for Tandem Diabetes Care and 4 mentions for Monogram Orthopaedics. Tandem Diabetes Care's average media sentiment score of 0.80 beat Monogram Orthopaedics' score of 0.11 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	14 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Monogram Orthopaedics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer TNDM or MGRM?

Tandem Diabetes Care currently has a consensus target price of $22.67, suggesting a potential upside of 107.00%. Monogram Orthopaedics has a consensus target price of $5.40, suggesting a potential upside of 1.41%. Given Tandem Diabetes Care's higher probable upside, equities analysts clearly believe Tandem Diabetes Care is more favorable than Monogram Orthopaedics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Monogram Orthopaedics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Which has better earnings and valuation, TNDM or MGRM?

Monogram Orthopaedics has lower revenue, but higher earnings than Tandem Diabetes Care. Monogram Orthopaedics is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$940.20M	0.79	-$96.03M	-$3.09	-3.54
Monogram Orthopaedics	N/A	N/A	-$16.33M	-$0.50	-10.65

Which has more volatility and risk, TNDM or MGRM?

Tandem Diabetes Care has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Monogram Orthopaedics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Summary

Tandem Diabetes Care beats Monogram Orthopaedics on 9 of the 16 factors compared between the two stocks.